Which has better earnings and valuation, CBIO or INVA?

Innoviva has higher revenue and earnings than Crescent Biopharma. Crescent Biopharma is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Crescent Biopharma $10.84M 43.45 -$153.94M -$10.91 N/A Innoviva $411.33M 4.00 $271.17M $6.01 3.71

Does the media refer more to CBIO or INVA?

In the previous week, Innoviva had 5 more articles in the media than Crescent Biopharma. MarketBeat recorded 7 mentions for Innoviva and 2 mentions for Crescent Biopharma. Innoviva's average media sentiment score of 0.61 beat Crescent Biopharma's score of 0.12 indicating that Innoviva is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crescent Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Innoviva 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CBIO or ZBIO more profitable?

Zenas BioPharma's return on equity of -99.99% beat Crescent Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Crescent Biopharma N/A -103.44% -88.19% Zenas BioPharma N/A -99.99% -58.06%

Does the media favor CBIO or ZBIO?

In the previous week, Crescent Biopharma had 1 more articles in the media than Zenas BioPharma. MarketBeat recorded 2 mentions for Crescent Biopharma and 1 mentions for Zenas BioPharma. Crescent Biopharma's average media sentiment score of 0.12 beat Zenas BioPharma's score of 0.00 indicating that Crescent Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crescent Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zenas BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer NVAX or CBIO?

In the previous week, Novavax had 1 more articles in the media than Crescent Biopharma. MarketBeat recorded 3 mentions for Novavax and 2 mentions for Crescent Biopharma. Novavax's average media sentiment score of 0.43 beat Crescent Biopharma's score of 0.12 indicating that Novavax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Crescent Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CBIO or MNKD?

In the previous week, MannKind had 1 more articles in the media than Crescent Biopharma. MarketBeat recorded 3 mentions for MannKind and 2 mentions for Crescent Biopharma. Crescent Biopharma's average media sentiment score of 0.12 beat MannKind's score of -0.13 indicating that Crescent Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crescent Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MannKind 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer LXRX or CBIO?

In the previous week, Lexicon Pharmaceuticals and Lexicon Pharmaceuticals both had 2 articles in the media. Lexicon Pharmaceuticals' average media sentiment score of 0.14 beat Crescent Biopharma's score of 0.12 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexicon Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Crescent Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Crescent Biopharma (CBIO) Competitors

$17.09 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$17.11 +0.02 (+0.15%)

As of 07/2/2026 04:37 PM Eastern

Compare

CBIO vs. INVA, ZBIO, NVAX, MNKD, and LXRX

Should you buy Crescent Biopharma stock or one of its competitors? MarketBeat compares Crescent Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Crescent Biopharma include Innoviva (INVA), Zenas BioPharma (ZBIO), Novavax (NVAX), MannKind (MNKD), and Lexicon Pharmaceuticals (LXRX). These companies are all part of the "biotechnology" industry.

How does Crescent Biopharma compare to Innoviva?

Crescent Biopharma (NASDAQ:CBIO) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

In the previous week, Innoviva had 5 more articles in the media than Crescent Biopharma. MarketBeat recorded 7 mentions for Innoviva and 2 mentions for Crescent Biopharma. Innoviva's average media sentiment score of 0.61 beat Crescent Biopharma's score of 0.12 indicating that Innoviva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crescent Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Innoviva	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Crescent Biopharma currently has a consensus target price of $29.00, suggesting a potential upside of 69.69%. Innoviva has a consensus target price of $36.20, suggesting a potential upside of 62.26%. Given Crescent Biopharma's stronger consensus rating and higher probable upside, equities analysts plainly believe Crescent Biopharma is more favorable than Innoviva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crescent Biopharma	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Crescent Biopharma has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, Innoviva has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market.

Innoviva has higher revenue and earnings than Crescent Biopharma. Crescent Biopharma is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crescent Biopharma	$10.84M	43.45	-$153.94M	-$10.91	N/A
Innoviva	$411.33M	4.00	$271.17M	$6.01	3.71

75.2% of Crescent Biopharma shares are held by institutional investors. Comparatively, 99.1% of Innoviva shares are held by institutional investors. 4.0% of Crescent Biopharma shares are held by insiders. Comparatively, 2.0% of Innoviva shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Innoviva has a net margin of 119.89% compared to Crescent Biopharma's net margin of 0.00%. Innoviva's return on equity of 33.33% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crescent Biopharma	N/A	-103.44%	-88.19%
Innoviva	119.89%	33.33%	22.67%

Summary

Innoviva beats Crescent Biopharma on 11 of the 17 factors compared between the two stocks.

How does Crescent Biopharma compare to Zenas BioPharma?

Crescent Biopharma (NASDAQ:CBIO) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

In the previous week, Crescent Biopharma had 1 more articles in the media than Zenas BioPharma. MarketBeat recorded 2 mentions for Crescent Biopharma and 1 mentions for Zenas BioPharma. Crescent Biopharma's average media sentiment score of 0.12 beat Zenas BioPharma's score of 0.00 indicating that Crescent Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crescent Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zenas BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zenas BioPharma's return on equity of -99.99% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crescent Biopharma	N/A	-103.44%	-88.19%
Zenas BioPharma	N/A	-99.99%	-58.06%

Crescent Biopharma has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.96, meaning that its stock price is 196% less volatile than the broader market.

Crescent Biopharma presently has a consensus price target of $29.00, indicating a potential upside of 69.69%. Zenas BioPharma has a consensus price target of $44.29, indicating a potential upside of 62.64%. Given Crescent Biopharma's stronger consensus rating and higher probable upside, equities analysts plainly believe Crescent Biopharma is more favorable than Zenas BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crescent Biopharma	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

75.2% of Crescent Biopharma shares are owned by institutional investors. 4.0% of Crescent Biopharma shares are owned by insiders. Comparatively, 22.0% of Zenas BioPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Crescent Biopharma has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crescent Biopharma	$10.84M	43.45	-$153.94M	-$10.91	N/A
Zenas BioPharma	$10M	171.90	-$377.74M	-$8.47	N/A

Summary

Crescent Biopharma beats Zenas BioPharma on 10 of the 16 factors compared between the two stocks.

How does Crescent Biopharma compare to Novavax?

Novavax (NASDAQ:NVAX) and Crescent Biopharma (NASDAQ:CBIO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

Novavax currently has a consensus price target of $13.00, indicating a potential upside of 33.47%. Crescent Biopharma has a consensus price target of $29.00, indicating a potential upside of 69.69%. Given Crescent Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Crescent Biopharma is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	3 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.22
Crescent Biopharma	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Novavax has higher revenue and earnings than Crescent Biopharma. Novavax is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.43	$440.30M	-$0.58	N/A
Crescent Biopharma	$10.84M	43.45	-$153.94M	-$10.91	N/A

In the previous week, Novavax had 1 more articles in the media than Crescent Biopharma. MarketBeat recorded 3 mentions for Novavax and 2 mentions for Crescent Biopharma. Novavax's average media sentiment score of 0.43 beat Crescent Biopharma's score of 0.12 indicating that Novavax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Crescent Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

53.0% of Novavax shares are owned by institutional investors. Comparatively, 75.2% of Crescent Biopharma shares are owned by institutional investors. 1.6% of Novavax shares are owned by insiders. Comparatively, 4.0% of Crescent Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Novavax has a beta of 2.43, meaning that its stock price is 143% more volatile than the broader market. Comparatively, Crescent Biopharma has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market.

Crescent Biopharma has a net margin of 0.00% compared to Novavax's net margin of -14.73%. Novavax's return on equity of -14.82% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-14.73%	-14.82%	1.23%
Crescent Biopharma	N/A	-103.44%	-88.19%

Summary

Novavax beats Crescent Biopharma on 9 of the 17 factors compared between the two stocks.

How does Crescent Biopharma compare to MannKind?

Crescent Biopharma (NASDAQ:CBIO) and MannKind (NASDAQ:MNKD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.

MannKind has higher revenue and earnings than Crescent Biopharma. MannKind is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crescent Biopharma	$10.84M	43.45	-$153.94M	-$10.91	N/A
MannKind	$348.97M	4.00	$5.86M	-$0.07	N/A

Crescent Biopharma has a net margin of 0.00% compared to MannKind's net margin of -6.63%. MannKind's return on equity of -11.21% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crescent Biopharma	N/A	-103.44%	-88.19%
MannKind	-6.63%	-11.21%	-3.92%

75.2% of Crescent Biopharma shares are owned by institutional investors. Comparatively, 49.6% of MannKind shares are owned by institutional investors. 4.0% of Crescent Biopharma shares are owned by company insiders. Comparatively, 2.6% of MannKind shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, MannKind had 1 more articles in the media than Crescent Biopharma. MarketBeat recorded 3 mentions for MannKind and 2 mentions for Crescent Biopharma. Crescent Biopharma's average media sentiment score of 0.12 beat MannKind's score of -0.13 indicating that Crescent Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crescent Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MannKind	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Crescent Biopharma has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market. Comparatively, MannKind has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market.

Crescent Biopharma currently has a consensus target price of $29.00, indicating a potential upside of 69.69%. MannKind has a consensus target price of $8.97, indicating a potential upside of 98.42%. Given MannKind's higher possible upside, analysts clearly believe MannKind is more favorable than Crescent Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crescent Biopharma	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

Crescent Biopharma beats MannKind on 9 of the 17 factors compared between the two stocks.

How does Crescent Biopharma compare to Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Crescent Biopharma (NASDAQ:CBIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.

Lexicon Pharmaceuticals has higher revenue and earnings than Crescent Biopharma. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexicon Pharmaceuticals	$49.80M	20.69	-$50.34M	-$0.07	N/A
Crescent Biopharma	$10.84M	43.45	-$153.94M	-$10.91	N/A

Lexicon Pharmaceuticals presently has a consensus price target of $4.55, suggesting a potential upside of 96.12%. Crescent Biopharma has a consensus price target of $29.00, suggesting a potential upside of 69.69%. Given Lexicon Pharmaceuticals' higher probable upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than Crescent Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Crescent Biopharma	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Lexicon Pharmaceuticals has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market. Comparatively, Crescent Biopharma has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market.

Crescent Biopharma has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -37.46%. Lexicon Pharmaceuticals' return on equity of -18.64% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexicon Pharmaceuticals	-37.46%	-18.64%	-11.79%
Crescent Biopharma	N/A	-103.44%	-88.19%

74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.2% of Crescent Biopharma shares are owned by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are owned by insiders. Comparatively, 4.0% of Crescent Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Lexicon Pharmaceuticals and Lexicon Pharmaceuticals both had 2 articles in the media. Lexicon Pharmaceuticals' average media sentiment score of 0.14 beat Crescent Biopharma's score of 0.12 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexicon Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Crescent Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Lexicon Pharmaceuticals and Crescent Biopharma tied by winning 8 of the 16 factors compared between the two stocks.

Get Crescent Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CBIO vs. The Competition

Export

Metric	Crescent Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$470.95M	$3.10B	$7.18B	$12.46B
Dividend Yield	N/A	2.05%	2.67%	6.49%
P/E Ratio	-1.57	20.06	27.75	24.70
Price / Sales	43.45	357.05	533.82	98.65
Price / Cash	N/A	57.49	49.26	57.09
Price / Book	1.19	4.32	10.96	6.46
Net Income	-$153.94M	$64.45M	$3.57B	$337.01M
7 Day Performance	-7.54%	2.97%	2.12%	1.70%
1 Month Performance	-7.31%	3.39%	2.80%	0.68%
1 Year Performance	7.55%	29.07%	33.40%	23.94%

Crescent Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
CBIO Crescent Biopharma	1.5927 of 5 stars	$17.09 flat	$29.00 +69.7%	+7.6%	$470.95M	$10.84M	N/A	50
INVA Innoviva	3.6329 of 5 stars	$22.71 -1.9%	$36.20 +59.4%	+16.2%	$1.71B	$411.33M	3.78	100
ZBIO Zenas BioPharma	2.8983 of 5 stars	$25.38 -0.7%	$44.29 +74.5%	+171.5%	$1.61B	$10M	N/A	N/A
NVAX Novavax	1.869 of 5 stars	$9.42 +0.6%	$13.00 +38.0%	+43.3%	$1.54B	$1.12B	N/A	1,990
MNKD MannKind	2.9187 of 5 stars	$4.26 +0.5%	$8.97 +110.5%	+25.4%	$1.31B	$348.97M	N/A	400

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CBIO) was last updated on 7/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Crescent Biopharma (CBIO) Competitors

CBIO vs. INVA, ZBIO, NVAX, MNKD, and LXRX

How does Crescent Biopharma compare to Innoviva?

Summary

How does Crescent Biopharma compare to Zenas BioPharma?

Summary

How does Crescent Biopharma compare to Novavax?

Summary

How does Crescent Biopharma compare to MannKind?

Summary

How does Crescent Biopharma compare to Lexicon Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBIO vs. The Competition

Crescent Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Crescent Biopharma (CBIO) Competitors

CBIO vs. INVA, ZBIO, NVAX, MNKD, and LXRX

How does Crescent Biopharma compare to Innoviva?

Does the media refer more to CBIO or INVA?

Do analysts rate CBIO or INVA?

Which has more volatility & risk, CBIO or INVA?

Which has better earnings and valuation, CBIO or INVA?

Do insiders & institutionals hold more shares of CBIO or INVA?

Is CBIO or INVA more profitable?

Summary

How does Crescent Biopharma compare to Zenas BioPharma?

Does the media favor CBIO or ZBIO?

Is CBIO or ZBIO more profitable?

Which has more volatility and risk, CBIO or ZBIO?

Do analysts recommend CBIO or ZBIO?

Do institutionals & insiders believe in CBIO or ZBIO?

Which has better valuation and earnings, CBIO or ZBIO?

Summary

How does Crescent Biopharma compare to Novavax?

Do analysts rate NVAX or CBIO?

Which has preferable earnings & valuation, NVAX or CBIO?

Does the media prefer NVAX or CBIO?

Do insiders and institutionals believe in NVAX or CBIO?

Which has more volatility and risk, NVAX or CBIO?

Is NVAX or CBIO more profitable?

Summary

How does Crescent Biopharma compare to MannKind?

Which has stronger valuation & earnings, CBIO or MNKD?

Is CBIO or MNKD more profitable?

Do insiders & institutionals believe in CBIO or MNKD?

Does the media favor CBIO or MNKD?

Which has more volatility & risk, CBIO or MNKD?

Do analysts recommend CBIO or MNKD?

Summary

How does Crescent Biopharma compare to Lexicon Pharmaceuticals?

Which has stronger valuation & earnings, LXRX or CBIO?

Do analysts rate LXRX or CBIO?

Which has more risk & volatility, LXRX or CBIO?

Is LXRX or CBIO more profitable?

Do insiders & institutionals have more ownership in LXRX or CBIO?

Does the media prefer LXRX or CBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBIO vs. The Competition

Crescent Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools